Gastrointestinal safety profile of XXXX : a meta-analysis and systematic review of randomized controlled trials.

@entity1 @entity548 @entity1066 @entity2210 @entity9213 @entity2247
This article provides a systematic review of the frequency and severity of adverse gastrointestinal (GI) events among @entity1 using @entity9213 , a @entity2247 -selective nonsteroidal anti-inflammatory drug (NSAID). A MEDLINE search of English language articles from 1990-1998, a manual search of citations from primary trials and review articles, and a manual search of proceedings from international gastroenterology meetings were conducted. Randomized clinical trials comparing the frequency of GI adverse events for @entity9213 versus non- @entity2247 -selective NSAIDs were selected. Specific data about the frequency of @entity2210 ; perforations, @entity1066 , and @entity548 (PUBs); and withdrawal of medication because of adverse GI events was also extracted. From a pool of 62 potentially relevant citations, 12 randomized trials were identified. All trials concerning symptomatic GI adverse events used the World Health Organization's Adverse Reaction Terminology List (WHO-ARTL) to code adverse events. @entity1 using @entity9213 had fewer GI adverse events compared with non- @entity2247 -selective NSAIDs (odds ratio = 0.64; 95% confidence interval [CI], 0.59-0.69). @entity1 using @entity9213 experienced less @entity2210 (odds ratio = 0.73; 95% CI, 0.64-0.84), fewer PUBs (odds ratio = 0.52; 95% CI, 0.28-0.96), and less frequent discontinuation of NSAID because of adverse GI events (odds ratio = 0.59; 95% CI, 0.52-0.67) compared with non- @entity2247 selective NSAIDs. @entity9213 , a @entity2247 -selective NSAID, appears to cause fewer adverse GI events than standard, non- @entity2247 -selective NSAIDs. However, the generalizability of these data may be limited by the low dose of @entity9213 used in most trials and the use of the WHO-ARTL to code adverse events.
